Previous 10 | Next 10 |
PhaseBio Pharmaceuticals (NASDAQ: PHAS ) is up 12% premarket on announcing financing and co-development collaboration with SFJ Pharmaceuticals for the development of PB2452, a reversal agent for the antiplatelet therapy ticagrelor. More news on: PhaseBio Pharmaceuticals, Inc....
PhaseBio to receive up to $120 million in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 MALVERN, Pa. and SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical c...
Gainers: Southwest Georgia Financial (NYSEMKT: SGB ) +48% . More news on: Southwest Georgia Financial Corporation, Rite Aid Corporation, Paratek Pharmaceuticals, Inc., Stocks on the move, Read more ...
I pray you, do not fall in love with me, for I am falser than vows made in wine. ” ― William Shakespeare, As You Like It Today, we take an in-depth look at a small ‘ Tier 4 ’ biotech stock that has taken shareholders for one wild ride since it debuted on the ...
MALVERN, Pa. and SAN DIEGO, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Execut...
PhaseBio Pharmaceuticals (NASDAQ: PHAS ): Q3 GAAP EPS of -$0.40 misses by $0.03 . More news on: PhaseBio Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Received Written End-of-Phase 1 Meeting Minutes Outlining Clear Development Path for PB2452 Completed Phase 2a Trial of PB2452 in Older and Elderly Subjects on Dual Antiplatelet Therapy Initiated Registrational Phase 2b Trial of PB2452 in Older and Elderly Subjects on Dual Antipla...
MALVERN, Pa. and SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that on November 14, ...
Thinly traded micro cap PhaseBio Pharmaceuticals ( PHAS +8.6% ) is up on below-average volume in reaction to its announcement that the first patient has been dosed in a Phase 2b clinical trial evaluating lead candidate PB2452 as a reversing agent of blood thinner ticagrelor (Ast...
MALVERN, Pa. and SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the first patien...
News, Short Squeeze, Breakout and More Instantly...
PhaseBio Pharmaceuticals Inc. Company Name:
PHAS Stock Symbol:
NASDAQ Market:
Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an upd...